16 March 2023
SHARE NOW
Cell Therapy
Collaborations, Mergers & Acquisitions
Gene Therapy
GMP
Logistics
Patient Access & Engagement
Regulatory & Standards
Scaling Up
Strategy
Supply Chain
Rupa Pike, Senior Director of Technical Affairs, Advanced Therapies, Thermo Fisher Scientific, joined us live at Advanced Therapies Week 2023 to discuss and shed some light on the current autologous vs allogeneic cell therapy landscape.
Discussing arguably one of the biggest debates in cell and gene therapy right now, autologous vs allogeneic, Rupa first takes a broad look at the market trends we are seeing in CGT development and manufacturing, before zooming in on the CDMO preparations, as well as supply chain and logistical considerations required for each method.
Rupa then goes on to consider the importance of mitigating manufacture risks in the unique regulatory environment that advanced therapies are developed and commercialized in, noting the benefits of collaboration to novel therapy delivery.
This interview has been produced in partnership with Thermo Fisher Scientific and was recorded at Advanced Therapies Week 2023.
 |
 |
More like this
Intensified extracellular vesicle production in fixed-bed bioreactors: Discover low-footprint, automated solutions for low-cost extracellular vesicles manufacturing
Are you looking for a cost-effective, high-productivity extracellular vesicle (EV) production platform that overcomes traditional manufacturing challenges? Join us to discover how Univercells Technologies’ scalable fixed-bed design is transforming EV manufacturing.
14 May 2024
Women in Advanced Therapies Global 2024, Virtual Event
Experience Women in Advanced Therapies Global, a 24-hour online event uniting the community in celebration of inspiration, innovation, and empowerment. Access exclusive insights, workshops, and networking opportunities from anywhere.
8 April 2024
